This study is looking at new ways to help nonhealing diabetic foot ulcers (sores on the feet that don't heal well) close. It compares two products, EPIEFFECT and EPIXPRESS, which are both made from human amnion/chorion membrane (a type of tissue), along with standard care, against standard care alone. Standard care includes cleaning, removing dead tissue, keeping the wound moist, and taking pressure off the foot. You might be able to join if you are at least 18 years old, have type 1 or 2 diabetes, and have a foot ulcer that has been present for 4 to 52 weeks and is between 0.7 and 5.0 square centimeters in size. The main goal is to see what percentage of ulcers close within 1 to 12 weeks. The current recruitment status is unclear.

Study design

This study will compare two different treatments plus standard care against standard care alone. It plans to include 170 participants.

What's involved

Participants will receive weekly treatment with either standard care alone or standard care plus EPIEFFECT or EPIXPRESS until their ulcer closes, or for a maximum of 12 weeks.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for wound closure is measured between 1 and 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.